What can knee pain treatment Glendale do for you?

What can the soreness tell me?

Wear-related soreness often builds during walks, stairs, or a long sit. It’ll sometimes ease as you move, then return that evening.

Mention any swelling, catching, locking, or giving way when you see your doctor. Those facts help the exam more than saying only that it hurts.

Joint wear can appear on an X-ray. It can’t tell how much you hurt, so walking and sleep matter too.

Here’s the useful truth: a sore knee doesn’t always mean surgery. What caused it, your health, and how the ache limits you all matter.

What can I do at home today?

Ease back when an activity stirs the knee. Don’t stop all movement; short walks and easy leg work can keep stiffness from taking over.

A brace or cane can steady you as you walk. A medicine you spread over the sore knee may help, but ask whether your other medicines make that skin medicine unsafe.

Don’t add activity until the knee settles by the next day. If it keeps getting worse, take your notes to an exam instead of guessing.

Keep the home care that helps while you consider other care. QC Kinetix offers regenerative treatments, its term for care based on a sample gathered from your own body; for platelet-rich plasma, or PRP, staff take blood from an arm, spin it until the platelets are concentrated, and return that portion to the knee, but the label isn’t a promised result.

Sources

1. In a 2-year, double-blind RCT of 140 patients with symptomatic knee OA and ultrasound synovitis, intra-articular triamcinolone 40 mg every 12 weeks caused significantly GREATER cartilage volume loss than saline (index-compartment cartilage thickness change -0.21 mm vs -0.10 mm; between-group difference -0.11 mm, 95% CI -0.20 to -0.03) with NO significant difference in pain (-1.2 vs -1.9 on the WOMAC Likert pain subscale).

   McAlindon TE, LaValley MP, Harvey WF, et al. — Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial.. JAMA, 2017. DOI: 10.1001/jama.2017.5283.

2. The RESTORE trial randomized 288 adults aged 50+ with symptomatic mild-to-moderate medial knee OA to three weekly leukocyte-poor PRP injections or saline placebo. At 12 months, pain change was -2.1 vs -1.8 points (difference -0.4; 95% CI -0.9 to 0.2; P=.17) and medial tibial cartilage volume change was -1.4% vs -1.2% (P=.81). 29 of 31 prespecified secondary outcomes showed no significant between-group difference. The authors concluded the findings 'do not support use of PRP for the management of knee OA.'

   Bennell KL, Paterson KL, Metcalf BR, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

3. A BMJ meta-analysis of 169 trials (21,163 participants) found viscosupplementation (hyaluronic acid injection) reduced knee OA pain by SMD -0.08 (95% CI -0.15 to -0.02) in the 24 large placebo-controlled trials — about 2.0 mm on a 100 mm scale, far below the prespecified 0.37 SMD minimal clinically important difference — and increased serious adverse events (RR 1.49, 95% CI 1.12 to 1.98). Trial sequential analysis showed conclusive evidence of clinical equivalence to placebo has existed since 2009.

   Pereira TV, Juni P, Saadat P, et al. — Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis.. BMJ, 2022. DOI: 10.1136/bmj-2022-069722.

4. A Bayesian network meta-analysis restricted to LARGE randomized trials (>=100 patients per group) of 18 intra-articular interventions in knee and hip OA found treatment effects were larger in the 35 high-risk-of-bias trials than in the 22 low/unclear-risk trials. Excluding high-risk trials, triamcinolone had the highest probability of exceeding the minimal important difference at weeks 2 and 6; hyaluronic acid had NO effect on pain (SMD -0.04, 95% CrI -0.19 to 0.11) but higher odds of dropouts due to adverse events (OR 2.01) and of serious adverse events (OR 1.86) than placebo. Effects of 16 of the 18 interventions were smaller than the MID and most were consistent with placebo.

   da Costa BR, et al. — Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomized trials: A systematic review and network meta-analysis.. Osteoarthritis and Cartilage, 2025. DOI: 10.1016/j.joca.2024.08.014.

5. FDA states verbatim: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production. There are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.